Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CLPB (SKD3) is a mitochondrial AAA+ ATPase disaggregase found in the intermembrane space of human mitochondria. It has a distinctive N-terminal ankyrin repeat domain, unlike other canonical AAA+ proteins, which is essential for its higher-order oligomeric assembly and disaggregase activity. The protein uses conserved pore-loops in its ATPase ring to grip and translocate substrate polypeptides, driven by ATP hydrolysis. Its activity regulates mitochondrial proteostasis by solubilizing aggregated mitochondrial proteins; proteolytic activation by PARL protease enhances its function. Mutations in CLPB cause severe metabolic and hematological disorders, such as 3-methylglutaconic aciduria type VII and congenital neutropenia, highlighting its critical roles in human biology and disease etiology[1][2][3][4].
For potential drugs, the expected mechanism would include: - Modulating ATPase activity (activation or inhibition) - Influencing ankyrin domain or rhomboid protease PARL-mediated cleavage (regulation of disaggregase activity) - Enhancing substrate solubilization/disaggregation (therapeutic activation)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Caseinolytic peptidase B protein homolog (CLPB).